News Center
NEWS CENTER
FDA approves ibrutinib for the treatment of chronic graft-versus-host disease ( cGVHD ) in children

FDA approves ibrutinib for the treatment of chronic graft-versus-host disease ( cGVHD ) in children

Syncozymes's annual production of 100 tons of coenzyme NMN/NADH/NAD series products will be officially put into production in October this year!

MORE

03

2022-08

Big news: Syncozymes has an annual output of 100 tons of coenzyme NMN/NADH/NAD series. These ingredients will be put into production

Syncozymes's annual production of 100 tons of coenzyme NMN/NADH/NAD series products will be officially put into production in October this year!

25

2022-07

Big News! SyncoZymes (Shanghai) Co., Ltd , The world's first NMN raw material passed FDA NDI certification.

After strict review by the professional committee of the US FDA (US Food and Drug Administration) authoritative organization, on May 17, 2022, SyncoZymes (Shanghai) Co., Ltd. officially received the FDA's confirmation letter (AKL): NMN raw material successfully passed NDI (New Dietary Ingredient) approval.

15

2021-01

Good news: Syncozymes has been recognized as a high-tech achievement transformation project

On January 5, 2021, Shangke Biopharmaceutical (Shanghai) Co., Ltd. was awarded the "(S)-1-tert-butoxycarbonyl-3-hydroxypiperidine" Shanghai High-tech Achievement Transformation Project.

13

2020-11

[During the Expo]: Syncozymes won the title of the first batch of enterprises to settle in the "Global Matchmaking Club"

The "Global Matchmaking Club" cross-border matchmaking platform is independently developed by ICBC and is open to global enterprises free of charge. Matching activities” and other core functions. Since the platform was launched for more than two months, it has attracted nearly 20,000 enterprises to settle in, covering more than 40 countries and regions, covering more than 30 industries such as food and medicine, energy and chemical industry, and technical equipment. The platform is committed to conforming to the general trend of open and cooperative world economic development, serving the new development pattern with the concept of inclusive finance, and continuously contributing financial positive energy to the building of an open world economy.

28

2020-10

Syncozymes and Zhejiang Supor Pharmaceutical Co., Ltd. participated in the 2020 Nanjing API CHINA API Exhibition and made a special academic report on NMN

On October 14, 2020, the 85th China International Pharmaceutical API/Intermediate/Packaging/Equipment Fair (referred to as API China API) opened at the Nanjing International Expo Center. Shangke Bio and Zhejiang Supor Pharmaceutical Co., Ltd. participated in the 2020 Nanjing API CHINA API Exhibition. Dr. Zhu, General Manager of Shangke Biology, made a special academic report on "NMN's Past, Present and Future" at the exhibition.

×